National Bank of Canada
AGIO icon

National Bank of Canada’s Agios Pharmaceuticals AGIO Stock Holding History

National Bank of Canada’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$44 – 2919
2024
Q3 		$44 Buy
+1
New +$45 ﹤0.01% 2599

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

National Bank of Canada's AGIO Position: Q4 2024 in Review

National Bank of Canada sold out of Agios Pharmaceuticals (AGIO) in Q4 2024, closing a stake of 1 share — an estimated $44 sold.

National Bank of Canada first reported a position in AGIO in Q3 2024 and held it in 1 quarter. The position peaked at $44 in Q3 2024. 225 funds tracked by Wall St. Rank hold AGIO as of Q4 2024.

  • National Bank of Canada reported no remaining Agios Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • National Bank of Canada sold 1 Agios Pharmaceuticals share in Q4 2024, an estimated $44.
  • National Bank of Canada first reported a position in Agios Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • National Bank of Canada's Agios Pharmaceuticals position peaked at $44 in Q3 2024.
  • 225 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2024.

Based on National Bank of Canada's 13F filing for Q4 2024, filed 12 Feb 2025.